EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

Subjects will be initiated on subcutaneous (SC) or intravenous (IV) treprostinil and titrated
to a dose that improves the symptoms of PAH while minimizing excessive pharmacologic effects.
After achieving a minimum SC/IV treprostinil dose of 20 ng/kg/min, subjects may begin a
transition to oral treprostinil at the Transition Visit, which can occur at the Week 2, 4, or
8 study visit. After the Transition Visit, oral treprostinil titration will continue through
Week 16 to reach the maximum tolerated dose.

Inclusion Criteria:

1. Subjects who voluntary give written informed consent to participate in study

2. Males and female subjects aged 18 to 75 years at Screening (date the subject provides
written informed consent to participate in study)

3. Subjects with a diagnosis of WHO Group 1 pulmonary hypertension: symptomatic
idiopathic or heritable PAH; or PAH associated with connective tissue disease, human
immunodeficiency virus (HIV) infection, repaired congenital systemic-to-pulmonary
shunt (at least 1 year since repair with respect to the date of providing informed
consent), or appetite suppressant/toxin use

4. Subjects with WHO FC III symptoms at Baseline

5. Subjects with 6MWD >250 meters at Baseline

6. Subjects who are currently being treated with 1 or 2 oral FDA-approved PAH therapies
consisting of an endothelin receptor antagonist (ERA) and/or either a
phosphodiesterase type-5 inhibitor (PDE5-I) or a soluble guanylate cyclase (sGC)
stimulator for ≥3 months, and on a stable dose for ≥30 days prior to the Baseline
Visit

7. Subjects should be on stable doses of other medical therapies for at least 10 days
prior to the Baseline Visit, with no dose adjustments, additions, or discontinuations.
Exceptions to this are discontinuation or dose changes of anticoagulants and/or
diuretics. Subjects should not have experienced recent changes to non-pharmacologic
interventions, such as exercise, diet plans, pulmonary rehabilitation, sleep apnea
treatment, etc for at least 10 days prior to Baseline Visit.

8. Subjects with historical right-heart catheterization (RHC) with results consistent
with WHO Group 1 PAH, as demonstrated by pulmonary artery pressure mean of ≥25 mmHg, a
pulmonary artery wedge pressure (PAWP) or left ventricular end-diastolic pressure ≤15
mmHg if a PAWP measurement is not available, and absence of unrepaired congenital
heart disease (other than patent foramen ovale)

9. Subject has undergone a RHC within 180 days of Baseline and had a cardiac index >2.2
L/min/m^2 with no changes in their PAH medication regimen (ie, both dosing and drug)
since the RHC.

10. Subjects in whom their most recent historical echocardiography demonstrates clinically
normal left systolic and diastolic ventricular function and absence of any clinically
significant left-sided heart disease. Subjects with clinically insignificant left
ventricular diastolic dysfunction due to the effects of right ventricle (RV) overload
(RV hypertrophy and/or RV dilation) are eligible.

11. Subjects who agree to follow the specified precautions to avoid pregnancy as follows:

- Subjects who are females of childbearing potential include any female subject who
has experienced menarche and who has not undergone successful surgical
sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy)
or is not postmenopausal (defined as amenorrhea for at least 12 consecutive
months). For female subjects of childbearing potential, a negative urine
pregnancy test is required at Screening and Baseline prior to initiating study
drug. Female subjects of childbearing potential must follow 1 of the following
approaches:

- Practice actual abstinence from intercourse

- Have a partner with a vasectomy

- Have an intrauterine device

- Must use 2 different forms of highly effective contraception for the
duration of the study, and for at least 48 hours after discontinuing study
drug. Medically acceptable forms of effective contraception include approved
hormonal contraceptives (such as birth control pills) or barrier methods
(such as a condom or diaphragm).

- Male subjects with a partner of childbearing potential must use a condom during
intercourse for the duration of the study, and for 48 hours after discontinuing
study drug.

12. Human immunodeficiency virus-positive subjects must have a CD4 lymphocyte count of at
least 200 cells/mm^3 within 30 days of Screening and be receiving current standard of
care anti-retroviral or other effective medication for the treatment of HIV, with no
changes for at least 8 weeks prior to enrollment.

13. Subjects who, in the opinion of the Investigator, are capable of communicating
effectively with study personnel and are considered reliable, willing, and likely to
be cooperative with protocol requirements and attend all required study visits

14. Subjects who have the capability to answer surveys and questionnaires written in
English

Exclusion Criteria:

1. Female subjects who are pregnant, lactating, or planning to become pregnant during the
study

2. Subjects with a current diagnosis of uncontrolled sleep apnea, as defined by their
physician

3. Subjects with renal insufficiency, as defined by requiring dialysis or an estimated
creatinine clearance of <30 mL/min, as calculated by the Cockcroft-Gault equation

4. Subjects with liver dysfunction defined as elevated liver function tests (alanine
aminotransferase or aspartate aminotransferase) ≥3 times the upper limit of normal at
Screening, or subjects with Child-Pugh Class B or C hepatic disease

5. Subjects with anemia, as defined by Screening hemoglobin <9 g/dL

6. Subjects with an active infection or condition that would interfere with
interpretation of study assessments

7. Subjects with a history of ischemic heart disease (defined as subjects who require
anti-anginal therapy within 6 months of Screening or who have experienced a documented
myocardial infarction within 6 months of Screening), or a history of left-sided
myocardial dysfunction, as evidenced by a PAWP >15 mmHg or left ventricular ejection
fraction <50%

8. Subjects with uncontrolled systemic hypertension, as evidenced by systolic blood
pressure >160 mmHg or diastolic blood pressure >100 mmHg at Baseline

9. Subjects with severe hypotension, as evidenced by systolic blood pressure <90 mmHg or
diastolic blood pressure <50 mmHg at Baseline

10. If a lung assessment has been completed as per standard of care, any subject with 1 or
more of the following signs of documented relevant lung disease within 180 days of
Baseline: total lung capacity <60% of predicted, or forced expiratory volume in 1
second <55% of predicted normal

11. Subjects with chronic musculoskeletal disorder or any other disease that would limit
ambulation, or who are connected to a machine that is not portable

12. Subjects with a history of alcohol abuse or illicit drug use within 12 months of
Baseline

13. Subjects with any other concomitant disease with life expectancy of <12 months from
Baseline

14. Subjects with an unstable psychiatric condition or those not capable of understanding
the objectives, nature, or consequences of the study, or who have any condition which,
in the Investigator's opinion, would constitute an unacceptable risk to the subject's
safety

15. Subjects who are currently receiving an investigational drug, have an investigational
device in place, or who have participated in an investigational drug or device study
within 180 days prior to Baseline. Participation in an observational study within 180
days prior to Baseline does not disqualify a subject from enrolling.

16. Subjects who have received a prostacyclin-class therapy within 28 days of Baseline.

17. Subjects who have a Registry to Evaluate Early and Long-Term PAH Disease Management
(REVEAL) 2.0 Risk Score of 10 or greater.